Devices & Intervention · Note 08
Cardiologist explains why TAVR may be beneficial for select patients with moderate aortic stenosis
Cardiologist Philippe Genereux says moderate aortic stenosis should no longer be seen as benign, based on the PROGRESS trial of TAVR in this population.
Aortic stenosis is usually treated when it becomes severe and symptomatic. Moderate stenosis has often been watched, on the assumption that the valve is not yet narrow enough to justify intervention. The PROGRESS trial tested that assumption by treating selected patients earlier.
In the interview, Dr Philippe Genereux argues that moderate aortic stenosis should not be seen as a benign entity. The reasoning is that the valve disease is progressive and that waiting allows ventricular damage to accumulate. If earlier intervention prevents that damage, the threshold for treatment could shift.
Earlier intervention also means exposing patients to procedural risk before symptoms force the issue, so selection is critical. The trial's inclusion criteria, imaging thresholds and outcomes should be read carefully. This is a specialist discussion of a highly anticipated trial, not a recommendation to treat every moderate valve.
Keep in mind
- PROGRESS tested earlier TAVR in selected patients.
- Selection criteria determine whether earlier treatment helps.
Source and reuse
This is an independent editorial summary written for Heartline. It is not a verbatim reproduction and does not reproduce paywalled text. Reporting, data and quotations belong to Cardiovascular Business. Read the original at the link provided.
Metadata basis: the publisher’s public RSS feed and the abstract it exposes. Where the full article could not be accessed, this note is explicitly metadata-based and limited to what the feed disclosed. It is not medical advice.
Read the original at Cardiovascular Business →